[
  {
    "trial": "T027",
    "source": "fulltext",
    "arms": {
      "Intervention group": {"randomized": null, "analysed": null},
      "Control group": {"randomized": null, "analysed": null}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": -1, "form": "mean_sd", "location": "Table 2",
       "values": {"Intervention group": {"mean": "13.78", "sd": "3.87", "n": null}, "Control group": {"mean": "13.79", "sd": "4.78", "n": null}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "mean_sd", "location": "Table 2",
       "values": {"Intervention group": {"mean": "11.82", "sd": "3.41", "n": null}, "Control group": {"mean": "14.34", "sd": "4.29", "n": null}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 28, "form": "mean_sd", "location": "Table 2",
       "values": {"Intervention group": {"mean": "10.84", "sd": "3.48", "n": null}, "Control group": {"mean": "13.09", "sd": "3.79", "n": null}}}
    ],
    "pain": [],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "Table 2 labels its columns 'Nesdonal group' (thiopental only, the control) and 'Ketamine-Nesdonal group' (the intervention), Nesdonal first; mapped to Control group and Intervention group. The paper's labelling is not fully consistent: Table 1 gives maternal age 27.40 (4.09) to the Intervention group, while the Results text gives 27.4±4.09 to the Nesdonal group. Table 2's labels agree with the text's account of the within-group trends (ketamine group falling at 2 and 4 weeks, Nesdonal group rising at 2 weeks). Days: 'before caesarian section' = -1, 'two weeks after' = 14, 'four weeks after' = 28. No n per arm or per time is printed: the Results say only 'In total, 67 participants were studied in both groups', which could mean 67 in all or 67 per group (Table 1's category counts look like 67 per column, but no per-arm n is stated), so randomized and analysed are left blank. No adverse events, blinding check, enrollment dates, or registration are reported."
  },
  {
    "trial": "T037",
    "source": "registry",
    "arms": {
      "Low-Dose Ketamine (LDK) Treatment Group": {"randomized": "1", "analysed": "0"},
      "Control Group": {"randomized": "0", "analysed": "0"}
    },
    "depression": [],
    "pain": [],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "NCT05229653", "date": null},
    "note": "Registry results only. Participant flow: STARTED 1 (LDK) and 0 (Control); COMPLETED 0 and 0; NOT COMPLETED 1 and 0; randomized is taken from STARTED. Every outcome (pelvic pain VAS, GAD-7, MADRS at baseline and POD 1, 27, 55 and 83; EHP-30; change in opioid use) lists 'Analysed: 0' in each arm with no values, so there are no depression or pain entries. Adverse events (1 day): LDK serious 0/1, other 0/1; Control serious 0/0, other 0/0. None of the codebook's adverse-event categories (nor an any-AE count) is reported as such, so adverse_events is empty. No enrollment dates or registration date are given."
  },
  {
    "trial": "T046",
    "source": "library",
    "arms": {
      "Placebo group": {"randomized": "100", "analysed": "97"},
      "Low-dose esketamine group (1 mg/kg PCIA)": {"randomized": "100", "analysed": "99"},
      "High-dose esketamine group (2 mg/kg PCIA)": {"randomized": "100", "analysed": "99"}
    },
    "depression": [
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": -1, "form": "median_iqr", "location": "Results 3.3, text (EPDS median (IQR) on antenatal day 1)",
       "values": {"Placebo group": {"median": "12.0", "q1": "11.0", "q3": "13.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "12.0", "q1": "10.0", "q3": "13.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "11.0", "q1": "10.0", "q3": "13.0", "n": null}}},
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": 7, "form": "count", "definition": "EPDS > 9", "location": "Table 2",
       "values": {"Placebo group": {"events": "29", "n": "97"}, "Low-dose esketamine group (1 mg/kg PCIA)": {"events": "11", "n": "99"}, "High-dose esketamine group (2 mg/kg PCIA)": {"events": "7", "n": "99"}}},
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": 42, "form": "count", "definition": "EPDS > 9", "location": "Table 2",
       "values": {"Placebo group": {"events": "27", "n": "97"}, "Low-dose esketamine group (1 mg/kg PCIA)": {"events": "14", "n": "99"}, "High-dose esketamine group (2 mg/kg PCIA)": {"events": "9", "n": "99"}}},
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": 7, "form": "median_iqr", "location": "Results 3.3, text (EPDS score at 7 days; Fig. 2 prints no values)",
       "values": {"Placebo group": {"median": "7.0", "q1": "4.0", "q3": "10.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "5.0", "q1": "2.0", "q3": "7.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "4.0", "q1": "1.0", "q3": "7.0", "n": null}}},
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": 42, "form": "median_iqr", "location": "Results 3.3, text (EPDS score at 42 days; Fig. 2 prints no values)",
       "values": {"Placebo group": {"median": "6.0", "q1": "3.0", "q3": "10.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "5.0", "q1": "2.0", "q3": "8.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "3.0", "q1": "1.0", "q3": "7.0", "n": null}}},
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": 7, "form": "change_median_iqr", "location": "Results 3.3, text (change from antenatal day 1; Fig. 3 prints no values)",
       "values": {"Placebo group": {"median": "-5.0", "q1": "-9.0", "q3": "-2.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "-7.0", "q1": "-10.0", "q3": "-4.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "-8.0", "q1": "-10.0", "q3": "-5.0", "n": null}}},
      {"measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)", "day": 42, "form": "change_median_iqr", "location": "Results 3.3, text (change from antenatal day 1; Fig. 3 prints no values)",
       "values": {"Placebo group": {"median": "-6.0", "q1": "-9.0", "q3": "-2.5", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "-7.00", "q1": "-10.0", "q3": "-4.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "-8.0", "q1": "-10.0", "q3": "-5.0", "n": null}}}
    ],
    "pain": [
      {"measure": "NRS postoperative pain", "day": 1, "form": "median_iqr", "location": "Results 3.3, text (NRS at rest at 24 h; Fig. 4a prints no values)",
       "values": {"Placebo group": {"median": "2.0", "q1": "2.0", "q3": "3.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "2.0", "q1": "1.0", "q3": "2.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "2.0", "q1": "1.0", "q3": "3.0", "n": null}}},
      {"measure": "NRS postoperative pain", "day": 2, "form": "median_iqr", "location": "Results 3.3, text (NRS at rest at 48 h; Fig. 4a prints no values)",
       "values": {"Placebo group": {"median": "2.0", "q1": "2.0", "q3": "2.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "1.0", "q1": "1.0", "q3": "2.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "1.0", "q1": "1.0", "q3": "2.0", "n": null}}},
      {"measure": "NRS score on movement", "day": 2, "form": "median_iqr", "location": "Results 3.3, text (NRS on movement at 48 h; Fig. 4b prints no values)",
       "values": {"Placebo group": {"median": "4.0", "q1": "3.0", "q3": "5.0", "n": null}, "Low-dose esketamine group (1 mg/kg PCIA)": {"median": "4.0", "q1": "3.0", "q3": "4.0", "n": null}, "High-dose esketamine group (2 mg/kg PCIA)": {"median": "3.0", "q1": "3.0", "q3": "4.0", "n": null}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "location": "Table 3, Intraoperative events",
       "values": {"Placebo group": {"hallucination": "0", "dissociation": "0", "visual": "0", "dizziness": "2"}, "Low-dose esketamine group (1 mg/kg PCIA)": {"hallucination": "2", "dissociation": "3", "visual": "1", "dizziness": "11"}, "High-dose esketamine group (2 mg/kg PCIA)": {"hallucination": "1", "dissociation": "1", "visual": "2", "dizziness": "14"}}},
      {"window": "postoperative", "location": "Table 3, Postoperative events (6 h, 24 h and 48 h)",
       "values": {"Placebo group": {"dizziness": "3"}, "Low-dose esketamine group (1 mg/kg PCIA)": {"dizziness": "4"}, "High-dose esketamine group (2 mg/kg PCIA)": {"dizziness": "3"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2020-12", "end": "2022-01", "location": "Methods 2.1 ('conducted ... from December 2020 to January 2022'); the Results give no dates"},
    "registration": {"number": "ChiCTR-ROC-2000039069", "date": null},
    "note": "Randomized 100 per arm (Results 3.1); analysed n = 99 (2 mg), 99 (1 mg), 97 (placebo) from the headers of Tables 1-3 and the abstract (295 completed). Tables print the esketamine columns first (2 mg, 1 mg), then placebo. EPDS medians and changes from baseline are only in the Results text (Figs 2 and 3 print no values) and carry no n; the change values are median (IQR) of change, entered as change_median_iqr. The source prints minus signs as U+2212 followed by a space ('− 8.0'); written here as '-8.0'. Baseline 'antenatal day 1' coded day -1. Table 2 also gives remission (EPDS < 6) counts, not entered because they count participants without depression: 7 days 68 (68.7) [2 mg], 56 (56.6) [1 mg], 34 (35.1) [placebo]; 42 days 68 (68.7), 58 (58.6), 39 (40.2); plus ORs vs placebo for PDS and remission. Pain: NRS at rest (6, 24 and 48 h) entered under the design's 'NRS postoperative pain'; NRS on movement is a second measure the design doesn't list, entered under the source's name; the 6 h values fall outside the day windows; NRS on movement at 24 h has no printed values ('no significant differences'). Adverse events: visual = Table 3's nystagmus row; dysphoria (intraoperative 1, 1, 0 for 2 mg, 1 mg, placebo), muscular hypertonia, nausea, vomit, shiver, hypertension and cold sweat are not codebook categories; the text's 'several mild psychiatric adverse effects' gives no count. Blinding: the Limitations say participants were not asked which group they thought they were in, so there is no blinding check."
  },
  {
    "trial": "T050",
    "source": "fulltext",
    "arms": {
      "Ketamine group": {"randomized": null, "analysed": "15"},
      "Placebo group": {"randomized": null, "analysed": "15"}
    },
    "depression": [
      {"measure": "Patient Health Questionnaire-2 (PHQ-2)", "day": -1, "form": "count", "definition": "PHQ-2 ≥ 3", "location": "Table 1",
       "values": {"Ketamine group": {"events": "3", "n": "15"}, "Placebo group": {"events": "2", "n": "15"}}},
      {"measure": "Patient Health Questionnaire-2 (PHQ-2)", "day": -1, "form": "difference", "location": "Table 3, Baseline column",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.75",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "Patient Health Questionnaire-2 (PHQ-2)", "day": 7, "form": "difference", "location": "Table 3, POD 7 column",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.96",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}}
    ],
    "pain": [
      {"measure": "BPI pain severity subscale", "day": 1, "form": "difference", "location": "Table 3, row 'BPI mean', POD 1",
       "estimate": "-0.50", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.55",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI pain severity subscale", "day": 2, "form": "difference", "location": "Table 3, row 'BPI mean', POD 2",
       "estimate": "0.25", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.82",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI average", "day": 1, "form": "difference", "location": "Table 3, POD 1",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.65",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI average", "day": 2, "form": "difference", "location": "Table 3, POD 2",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.92",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI worst", "day": 1, "form": "difference", "location": "Table 3, POD 1",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.90",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI worst", "day": 2, "form": "difference", "location": "Table 3, POD 2",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.90",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI least", "day": 1, "form": "difference", "location": "Table 3, POD 1",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.61",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI least", "day": 2, "form": "difference", "location": "Table 3, POD 2",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.97",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI current", "day": 1, "form": "difference", "location": "Table 3, POD 1",
       "estimate": "-1", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.23",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "BPI current", "day": 2, "form": "difference", "location": "Table 3, POD 2",
       "estimate": "-1", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.52",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "opioid usage", "day": 1, "form": "difference", "location": "Table 3, row 'Opioid use', POD 1",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.83",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}},
      {"measure": "opioid usage", "day": 2, "form": "difference", "location": "Table 3, row 'Opioid use', POD 2",
       "estimate": "0", "lower": null, "upper": null, "level": null, "scale": "median_difference", "p": "0.81",
       "values": {"Ketamine group": {"n": null}, "Placebo group": {"n": null}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "time": "POD 0, 30 minutes after the infusion (in the PACU)", "location": "Results, paragraph after Table 2",
       "values": {"Ketamine group": {"any_ae": "7"}, "Placebo group": {"any_ae": "7"}}},
      {"window": "postoperative", "time": "POD 1", "location": "Results, paragraph after Table 2",
       "values": {"Ketamine group": {"any_ae": "8"}, "Placebo group": {"any_ae": "5"}}}
    ],
    "blinding_check": {"who": "participants", "when": "POD 1", "values": null, "p": "0.07", "location": "Results, paragraph after Table 2 ('no statistically significant difference between groups in response to questioning regarding which group they believe they were assigned (p = 0.07)')"},
    "enrollment": {"start": "2021-04", "end": "2022-04", "location": "Methods, first paragraph ('from April 2021 to April 2022'); the Results give no dates"},
    "registration": {"number": "NCT04831736", "date": "05/04/2021"},
    "note": "The source calls the arms 'Ketamine' and 'Control' (or placebo); Control mapped to 'Placebo group'. Thirty-one were randomized in all; one withdrawn before the intervention was not analysed, but her arm is not stated, so per-arm randomized numbers are blank; Table 1 gives n = 15 per arm. Table 3 gives only Wilcoxon median differences (Ketamine minus Control) with p-values, no confidence intervals and no arm-level values, for BPI, opioid use and PHQ-2; entered as form 'difference' with scale 'median_difference' (not one of the codebook's scales) and the printed p added. The minus signs are U+2212 in the source, written here as '-'. 'BPI mean' is the pain severity subscale (the arithmetic mean of the four items), entered under the design's name; BPI average, worst, least and current are entered under the source's names. Table 3's PHQ-2 row has values only in the Baseline and POD 7 columns. The BCPQ was reported only on POD 7 (14 (93%) in each group with residual pain), so it has no day 1 or 2 entry. Adverse events: the counts of participants reporting 'some form of side effect' are spelled out in the source ('seven (46.7%) subjects in each group' on POD 0, 'eight (53.3%)' ketamine and 'five (33.3%)' placebo on POD 1) and entered as numerals; the drug was given in the PACU after surgery, so both are postoperative; Figure 3 (side effects by type) prints no values. Blinding check: participants guessed their allocation on POD 1, but only p = 0.07 is printed, no guesses by arm. Registration date is ClinicalTrials.gov 'first posted 05/04/2021' as printed (day/month order not stated)."
  },
  {
    "trial": "T061",
    "source": "fulltext",
    "arms": {
      "Group E": {"randomized": "79", "analysed": "78"},
      "Group C": {"randomized": "79", "analysed": "77"}
    },
    "depression": [
      {"measure": "HADS depression subscale (HADS-D)", "day": -1, "form": "median_iqr", "location": "Table 1 (Preoperative HADS-D scores)",
       "values": {"Group E": {"median": "1", "q1": "0", "q3": "3", "n": "78"}, "Group C": {"median": "2", "q1": "0", "q3": "4", "n": "77"}}},
      {"measure": "HADS depression subscale (HADS-D)", "day": 3, "form": "median_iqr", "location": "Table 2 (POD 3 HADS-D scores)",
       "values": {"Group E": {"median": "1", "q1": "0", "q3": "4", "n": "78"}, "Group C": {"median": "1", "q1": "0", "q3": "3", "n": "77"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 4 (row 'Nightmare')",
       "values": {"Group E": {"nightmare": "2"}, "Group C": {"nightmare": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-12-31", "end": "2024-03-31", "location": "Results, first paragraph ('Between December 31, 2023, and March 31, 2024')"},
    "registration": {"number": "ChiCTR2400080363", "date": null},
    "note": "HADS-D values are median (p25, p75) per the table notes; n from the table headers (Group E n=78, Group C n=77). Window for nightmares: Table 4 lists 'Nightmare 2 (2.6%) vs 0 (0%)' under the subheading 'Intraoperative complications', but the Methods list nightmares among postoperative complications and the Results text names them with the postoperative events, so it is coded postoperative. The other Table 4 complications (respiratory depression, body movement, hypoxemia, sinus bradycardia, nausea and vomiting, headache, shivering) are not codebook categories. No postoperative pain scores are reported (only intraoperative opioid doses), and the design lists no pain measure. The Methods give the period as December 30, 2023 to March 30, 2024; the Results' dates are used."
  },
  {
    "trial": "T090",
    "source": "fulltext",
    "arms": {
      "Control group (group C)": {"randomized": "30", "analysed": null},
      "Esketamine group S1": {"randomized": "30", "analysed": null},
      "Esketamine group S2": {"randomized": "30", "analysed": null},
      "Esketamine group S3": {"randomized": "30", "analysed": null}
    },
    "depression": [
      {"measure": "HADS depression subscale", "day": -1, "form": "mean_sd", "location": "Table 4 (Preoperative, 'HDAS-D')",
       "values": {"Control group (group C)": {"mean": "3.70", "sd": "1.57", "n": null}, "Esketamine group S1": {"mean": "3.23", "sd": "1.45", "n": null}, "Esketamine group S2": {"mean": "3.10", "sd": "1.57", "n": null}, "Esketamine group S3": {"mean": "3.62", "sd": "1.32", "n": null}}},
      {"measure": "HADS depression subscale", "day": null, "form": "mean_sd", "location": "Table 4 (Postoperativ[e], 'HDAS-D')",
       "values": {"Control group (group C)": {"mean": "3.42", "sd": "1.30", "n": null}, "Esketamine group S1": {"mean": "2.75", "sd": "1.35", "n": null}, "Esketamine group S2": {"mean": "3.13", "sd": "1.35", "n": null}, "Esketamine group S3": {"mean": "3.33", "sd": "1.33", "n": null}}}
    ],
    "pain": [
      {"measure": "NRS at rest (3, 6, 12, 24, 48 h)", "day": 1, "form": "median_iqr", "location": "Table 3 (static state, 24h)",
       "values": {"Control group (group C)": {"median": "1", "q1": "1", "q3": "1.25", "n": null}, "Esketamine group S1": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Esketamine group S2": {"median": "0", "q1": "0", "q3": "1", "n": null}, "Esketamine group S3": {"median": "0", "q1": "0", "q3": "1", "n": null}}},
      {"measure": "NRS at rest (3, 6, 12, 24, 48 h)", "day": 2, "form": "median_iqr", "location": "Table 3 (static state, 48h)",
       "values": {"Control group (group C)": {"median": "1", "q1": "0", "q3": "1", "n": null}, "Esketamine group S1": {"median": "1", "q1": "1", "q3": "1", "n": null}, "Esketamine group S2": {"median": "0", "q1": "0", "q3": "1", "n": null}, "Esketamine group S3": {"median": "0", "q1": "0", "q3": "1", "n": null}}},
      {"measure": "NRS during exercise (3, 6, 12, 24, 48 h)", "day": 1, "form": "median_iqr", "location": "Table 2 (exercise status, 24h)",
       "values": {"Control group (group C)": {"median": "2", "q1": "2", "q3": "2", "n": null}, "Esketamine group S1": {"median": "2", "q1": "1", "q3": "2", "n": null}, "Esketamine group S2": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Esketamine group S3": {"median": "1", "q1": "1", "q3": "1", "n": null}}},
      {"measure": "NRS during exercise (3, 6, 12, 24, 48 h)", "day": 2, "form": "median_iqr", "location": "Table 2 (exercise status, 48h)",
       "values": {"Control group (group C)": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Esketamine group S1": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Esketamine group S2": {"median": "0", "q1": "0", "q3": "1", "n": null}, "Esketamine group S3": {"median": "0", "q1": "0", "q3": "1", "n": null}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 9 (row 'Dizzy giddy', yes)",
       "values": {"Control group (group C)": {"dizziness": "5"}, "Esketamine group S1": {"dizziness": "4"}, "Esketamine group S2": {"dizziness": "2"}, "Esketamine group S3": {"dizziness": "3"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-03", "end": "2024-03", "location": "Methods, General information ('between March 2023 and March 2024'); the Results give no dates"},
    "registration": {"number": "ChiCTR2400090449", "date": null},
    "note": "Randomized 30 per group (Methods). No analysed n is stated; Tables 1, 7 and 9 show group S2 with 29 (for example Table 9 Diplopia 'No 29(100)') and the other groups with 30, so analysed is left blank. HADS-D is Table 4's 'HDAS-D' row (mean ± SD). The time of the postoperative HADS is not stated anywhere (Methods list HADS among 'postoperative assessments'), so its day is null. NRS cells are median (IQR); the source's significance superscripts (a, b) after S2 and S3 values are dropped; the 3, 6 and 12 h values fall outside the day windows. Not entered: sufentanil consumption (Table 8, total amount 37.30 ± 1.58, 36.90 ± 2.33, 27.48 ± 1.88, 21.73 ± 1.82 µg; timing not stated, given intermittently during maintenance) and remedial analgesia (Table 9, yes 10, 8, 6, 0; postoperative, no time). Adverse events: Table 9 'Dizzy giddy' yes entered as dizziness. The Diplopia row prints only 'No 30(100) 30(100) 29(100) 30(100)' (no 'yes' row), so no visual count is entered. The Nightmare row prints 'yes 30(100) 30(100) 29(100) 30(100)', which reads as every patient having nightmares and is presumably a mislabelled 'No' row (the text reports no difference in nightmares); not entered. Nausea and vomiting is not a codebook category. Single-blind; no blinding check."
  },
  {
    "trial": "T099",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "102", "analysed": "102"},
      "Saline group": {"randomized": "102", "analysed": "102"}
    },
    "depression": [
      {"measure": "HADS-D", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}, "Saline group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}}},
      {"measure": "HADS-D", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}, "Saline group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}}},
      {"measure": "HADS-D", "day": 2, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}, "Saline group": {"median": "2.5", "q1": "2", "q3": "3", "n": "102"}}},
      {"measure": "HADS-D", "day": 3, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}, "Saline group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}}},
      {"measure": "HADS-D", "day": 7, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "3", "n": null}, "Saline group": {"median": "3", "q1": "2", "q3": "3", "n": null}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "4", "n": "102"}, "Saline group": {"median": "4", "q1": "3", "q3": "4", "n": "102"}}},
      {"measure": "NRS at rest", "day": 2, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "2", "q1": "2", "q3": "3", "n": "102"}, "Saline group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}}},
      {"measure": "NRS after movement", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "4", "n": "102"}, "Saline group": {"median": "4", "q1": "3", "q3": "4", "n": "102"}}},
      {"measure": "NRS after movement", "day": 2, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "2", "q1": "1", "q3": "3", "n": "102"}, "Saline group": {"median": "3", "q1": "2", "q3": "3", "n": "102"}}}
    ],
    "adverse_events": [
      {"window": "emergence", "time": "within 1 h after surgery (Table 4 places it under 'Postoperative period')", "location": "Table 4",
       "values": {"Esketamine group": {"dizziness": "25", "agitation": "2", "hallucination": "0", "visual": "0"}, "Saline group": {"dizziness": "19", "agitation": "0", "hallucination": "0", "visual": "0"}}},
      {"window": "postoperative", "time": "1-24 h after surgery", "location": "Table 4",
       "values": {"Esketamine group": {"dizziness": "14", "agitation": "0", "hallucination": "0", "visual": "0"}, "Saline group": {"dizziness": "11", "agitation": "0", "hallucination": "0", "visual": "0"}}},
      {"window": "postoperative", "time": "24-72 h after surgery", "location": "Table 4",
       "values": {"Esketamine group": {"dizziness": "9", "agitation": "0", "hallucination": "0", "visual": "0"}, "Saline group": {"dizziness": "6", "agitation": "0", "hallucination": "0", "visual": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-05-05", "end": "2024-10-31", "location": "Methods ('Dates of first and last enrollments were May 5, 2024, and October 31, 2024'); the Results give no dates"},
    "registration": {"number": "NCT06388824", "date": null},
    "note": "The source calls the control 'Placebo group' (saline); mapped to 'Saline group'. Tables print the placebo column first. Intention-to-treat: 204 randomized, 102 per arm, all analysed; per-protocol 100 (placebo) and 101 (esketamine) after three declined day-7 follow-up. At day 7 Table 3 flags (2) placebo and (1) esketamine patients missing, so n is left blank there; at days 1-3 the column n (102) is used. Table 3 also gives Hodges-Lehmann median differences with 95% CIs (HADS-D: 0 (0 to 0) at every day; not entered since arm values are given). Pain at postoperative hour 1 falls outside the day windows. Postoperative acetaminophen use (13 (12.8) placebo vs 6 (5.9) esketamine) covers the first three postoperative days, so it has no day 1 or 2 entry. Adverse events: 'within 1 h after surgery' (recovery from the short propofol anaesthesia) coded emergence, the later Table 4 periods postoperative; visual = diplopia; agitation is Table 4's 'Agitation' row only. Delirium (within 1 h: 1 placebo, 4 esketamine; 0 at later periods), somnolence and memory impairment are separate rows and not codebook categories. No intraoperative event in the codebook categories. No blinding check reported."
  },
  {
    "trial": "T100",
    "source": "fulltext",
    "arms": {
      "Esketamine group (PE)": {"randomized": "66", "analysed": "58"},
      "Control group (C)": {"randomized": "66", "analysed": "58"}
    },
    "depression": [
      {"measure": "HADS depression score", "day": 1, "form": "difference", "location": "Discussion, second paragraph",
       "estimate": "1.5", "direction": "lower in Esketamine group (PE) than in Control group (C)", "lower": null, "upper": null, "level": null, "scale": null,
       "values": {"Esketamine group (PE)": {"n": null}, "Control group (C)": {"n": null}}},
      {"measure": "HADS depression score", "day": 3, "form": "difference", "location": "Discussion, second paragraph",
       "estimate": "1.5", "direction": "lower in Esketamine group (PE) than in Control group (C)", "lower": null, "upper": null, "level": null, "scale": null,
       "values": {"Esketamine group (PE)": {"n": null}, "Control group (C)": {"n": null}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "location": "Results, Adverse Events and Block-Related Complications ('no patients in either group developed headache, blurred vision, delirium, or block-related complications')",
       "values": {"Esketamine group (PE)": {"visual": "0"}, "Control group (C)": {"visual": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-09", "end": "2024-02", "location": "Methods, Ethics and Participant Registration ('between September 2023 and February 2024 were included'); the Results give no dates"},
    "registration": {"number": "ChiCTR2300075055", "date": "August 23, 2023"},
    "note": "The source's Tables 1-7 are not in the text (web 'Download CSV / Display Table' placeholders), so no arm-level HADS-D, VAS or adverse-event counts are available; Figures 2 and 3 print no values. The only depression number is in the Discussion: 'group PE showed significantly lower HADS-D scores on postoperative days 1 and 3. Compared with group C, HADS-D scores were 1.5 points lower in group PE, and the between-group differences were statistically significant.' It is not said whether 1.5 applies to each day or is one figure for both, nor whether it is a mean or median difference (HADS was analysed by repeated-measures ANOVA), and no CI or exact p is given; entered at days 1 and 3 as a difference with scale null and the printed direction. No HADS-D numbers at baseline or day 7 (no significant differences). Randomized 66 per group; 116 completed; analysed n = 58 per group from the notes to Figures 2 and 3. VAS: 'No statistically significant differences', no values. Adverse events: only the zero for blurred vision is printed; Table 7's agitation, hallucination and dizziness counts are not in the source, and delirium (none) is a separate item from postoperative agitation, so agitation is not entered. No blinding check."
  },
  {
    "trial": "T120",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "168", "analysed": "164"},
      "Control group": {"randomized": "168", "analysed": "158"}
    },
    "depression": [
      {"measure": "EPDS", "day": -1, "form": "median_iqr", "location": "Table 1 (Baseline EPDS score)",
       "values": {"Esketamine group": {"median": "6", "q1": "4", "q3": "7", "n": "164"}, "Control group": {"median": "5", "q1": "3", "q3": "8", "n": "158"}}},
      {"measure": "EPDS", "day": 7, "form": "count", "definition": "EPDS ≥ 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "8", "n": "164"}, "Control group": {"events": "24", "n": "158"}}},
      {"measure": "EPDS", "day": 30, "form": "count", "definition": "EPDS ≥ 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "13", "n": "158"}, "Control group": {"events": "16", "n": "149"}}},
      {"measure": "EPDS", "day": 60, "form": "count", "definition": "EPDS ≥ 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "8", "n": "149"}, "Control group": {"events": "13", "n": "145"}}},
      {"measure": "EPDS", "day": 90, "form": "count", "definition": "EPDS ≥ 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "7", "n": "146"}, "Control group": {"events": "10", "n": "143"}}},
      {"measure": "EPDS", "day": 7, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "4", "q1": "2", "q3": "6", "n": null}, "Control group": {"median": "5", "q1": "2", "q3": "8", "n": null}}},
      {"measure": "EPDS", "day": 30, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "4", "q1": "2", "q3": "7", "n": null}, "Control group": {"median": null, "q1": "2", "q3": "7", "n": null}}},
      {"measure": "EPDS", "day": 60, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "4", "q1": "2", "q3": "7", "n": null}, "Control group": {"median": "4", "q1": "2", "q3": "7", "n": null}}},
      {"measure": "EPDS", "day": 90, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "3", "q1": "2", "q3": "5", "n": null}, "Control group": {"median": "4", "q1": "2", "q3": "7", "n": null}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "median_iqr", "location": "Results, Outcomes, text after Fig. 2 (NRS at 24 h; Fig. 3a prints no values)",
       "values": {"Esketamine group": {"median": "2", "q1": "1", "q3": "4", "n": null}, "Control group": {"median": "2", "q1": "1", "q3": "5", "n": null}}},
      {"measure": "sufentanil consumption", "day": 1, "form": "median_iqr", "location": "Results, Outcomes, text after Fig. 2 (median sufentanil in PCIA, μg; cumulative 24 h per Fig. 3c caption)",
       "values": {"Esketamine group": {"median": "60", "q1": null, "q3": null, "n": null}, "Control group": {"median": "62", "q1": null, "q3": null, "n": null}}},
      {"measure": "effective PCIA presses", "day": 1, "form": "median_iqr", "location": "Results, Outcomes, text after Fig. 2 (number of effective presses over the 24 h PCIA)",
       "values": {"Esketamine group": {"median": "6", "q1": "3", "q3": "10", "n": null}, "Control group": {"median": "7", "q1": "3.5", "q3": "11", "n": null}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "time": "within 1 h after drug administration (during caesarean section)", "location": "Table 3",
       "values": {"Esketamine group": {"dizziness": "18", "hallucination": "17", "visual": "3", "dissociation": "9"}, "Control group": {"dizziness": "0", "hallucination": "0", "visual": "0", "dissociation": "0"}}},
      {"window": "postoperative", "time": "24 h postpartum", "location": "Table 3; hallucination and dissociation zeros from the text after Table 3",
       "values": {"Esketamine group": {"dizziness": "21", "visual": "1", "hallucination": "0", "dissociation": "0"}, "Control group": {"dizziness": "9", "visual": "0", "hallucination": "0", "dissociation": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2021-05-01", "end": "2024-03-31", "location": "Methods, Study design ('conducted from 1 May 2021 to 31 March 2024'); the Results give no dates"},
    "registration": {"number": "NCT04860661", "date": "20 April 2021"},
    "note": "Randomized 168 per arm; modified intention-to-treat 164 (esketamine) and 158 (control). Days: 7 days = 7, 1 month = 30, 2 months = 60, 3 months = 90; baseline EPDS was taken the day before surgery. Count n are Table 2's denominators (n/total); the median rows print no n. Table 2 prints no control median at 1 month (the cell reads '[2 to 7]'), so that median is null; the median difference there is 0 (-1 to 0). Not entered: the total incidence of PPD within 3 months, given only as percentages (11.59% vs 20.89%; adjusted RR 0.57, 95% CI 0.35 to 0.94). Pain: the 24 h NRS is used for day 1 (the 18 h values, 2 [1 to 4] vs 2 [1 to 4], also fall in the day-1 window); sufentanil consumption is printed only as medians (60 and 62 μg) with no IQR; PCIA presses are over the 24 h PCIA (time not stated beside the numbers). Adverse events: Table 3's 'within 1 h after drug administration' events happened during the caesarean section (the text says they vanished before the end of surgery), so window intraoperative; visual = nystagmus (intraoperative) and diplopia (postoperative). The postoperative hallucination and dissociation zeros come from the sentence 'No patients experienced hallucination or dissociation after surgery.' Hallucinations were 12 euphoric, 3 unpleasant, 2 neutral; the unpleasant ones are not counted as nightmares. Nausea or vomiting is not a codebook category. No blinding check reported (allocation was revealed after the 3-month follow-up)."
  }
]